Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Suzanne Beck

Allergy Lubbock, TX Medical Doctor

NPI 1861597973 CMS profile 84203

3502 22Nd St, Erin Dutton, Lubbock, TX 79410

Open in the dashboard

General payments

$3,365

225 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Suzanne Beck of Lubbock, TX is reported in the CMS Open Payments database as having received $3,365 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $693 41
2021 General $1,042 60
2020 General $255 14
2019 General $1,375 110

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suzanne Beck
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Suzanne Beck were reported at $0. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Suzanne Beck Allergy median Middle half National median
2019 $1,375 $506 $151–$1,337 $163
2020 $255 $409 $108–$1,162 $114
2021 $1,042 $549 $125–$1,485 $132
2022 $693 $666 $161–$1,594 $149
2023 $0 $780 $186–$1,916 $160
2024 $0 $1,031 $271–$2,196 $164
2025 $0 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $751 61 payments
  2. AstraZeneca Pharmaceuticals LP $723 28 payments
  3. Teva Pharmaceuticals USA, Inc. $264 17 payments
  4. Regeneron Healthcare Solutions, Inc. $239 9 payments
  5. Amgen Inc. $210 7 payments
  6. Genzyme Corporation $167 10 payments
  7. AbbVie, Inc. $120 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $119 6 payments
  9. Mylan Specialty L.P. $119 7 payments
  10. Sunovion Pharmaceuticals Inc. $108 39 payments
  11. Other $546 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,365 225 payments
Products named General payments · program years 2019–2022
  1. TRELEGY ELLIPTA $321 31 payments
  2. SYMBICORT $263 14 payments
  3. NUCALA Respiratory $260 12 payments
  4. DUPIXENT Inflammation And Immunology $239 9 payments
  5. NUCALA Immunology $173 18 payments
  6. DUPIXENT Immunology $167 10 payments
  7. FASENRA $161 3 payments
  8. TEZSPIRE $158 2 payments
  9. FARXIGA $143 7 payments
  10. AirDuo Digihaler $129 8 payments
  11. Other $1,782 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record